Glenmark Pharmaceuticals, a global pharmaceutical company, announced, it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Limited (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.

“The agreement for these ophthalmic products is aligned with our strategy to strengthen our focus on complex generic formulations,” said Robert Matsuk, President, North America & Global API at Glenmark Pharmaceuticals. “Our strategic partnership with SCD supports our objective to expand the product offerings of our complex generic portfolio.”

It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the U.S. brand sales for the six products was approximately $1.7 billion for the calendar year 2017.